These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8873054)

  • 21. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
    Falkson CI; Falkson G; Falkson HC
    J Clin Oncol; 1991 Aug; 9(8):1403-8. PubMed ID: 2072144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
    Schultz MZ; Buzaid AC; Poo WJ
    Melanoma Res; 1997 Apr; 7(2):147-51. PubMed ID: 9167181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
    Mulder NH; van der Graaf WT; Willemse PH; Koops HS; de Vries EG; Sleijfer DT
    Br J Cancer; 1994 Oct; 70(4):681-3. PubMed ID: 7522510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemotherapy in the treatment of metastatic melanoma in selected patients.
    González Astorga B; Jiménez Rubiano B; Delgado Pérez JR; Valdivia Bautista J; Sánchez Toro C; González Flores E; Luque Caro R; Castellón Rubio V
    Clin Transl Oncol; 2009 Jun; 11(6):382-6. PubMed ID: 19531453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA flow cytometry and the outcome of chemoimmunotherapy in metastatic melanoma.
    Hahka-Kemppinen M; Muhonen T; Nordling S; Pyrhönen S
    Melanoma Res; 1997 Aug; 7(4):329-34. PubMed ID: 9293483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
    Hernberg M; Muhonen T; Turunen JP; Hahka-Kemppinen M; Pyrhönen S
    J Clin Oncol; 1996 May; 14(5):1690-6. PubMed ID: 8622089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
    Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
    Hernberg MM; Hahka-Kemppinen MH; Pyrhönen SO
    Melanoma Res; 2004 Dec; 14(6):493-500. PubMed ID: 15577320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemotherapy of malignant melanoma].
    Ishihara K
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):23-7. PubMed ID: 7529980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
    Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
    Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
    Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R
    Melanoma Res; 2003 Feb; 13(1):87-91. PubMed ID: 12569290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
    J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
    Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
    Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
    Falkson CI
    Med Oncol; 1995 Mar; 12(1):35-40. PubMed ID: 8542245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.
    Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Kähäri VM; Pyrhönen S
    Int J Cancer; 2002 Feb; 97(4):432-8. PubMed ID: 11802203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].
    Avril MF; Beerblock K; Dreno B; Delaunay M; Bonerandi JJ; Guillaume JC; Souteyrand P; Kalis B; Chevrant-Breton J; Verret J
    Bull Cancer; 1990; 77(12):1183-91. PubMed ID: 2081278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.